Approval and first showing
China's National Medical Products Administration has approved ZEISS PT LUNANA, a phakic intraocular lens, the company said. ZEISS Medical Technology described the lens as the first in its Phakic Technology family of phakic IOLs and said the approval is its first step in establishing a ZEISS phakic IOL portfolio. The company showed the lens at the 9th China International Import Expo in Shanghai and said it plans a release in the coming year, with commercialization in China first in 2027 and the platform eventually taken to the global stage.
What the numbers show
China has an estimated 600 million people with myopia, and roughly two in three people aged 15 to 19 have the condition, with 9.5% having high myopia, according to a systematic review the company cited. ZEISS said the lens uses an aspheric optical design and AQUAFLEX hydrophilic polymer material, and Professor Wang Xiaoying of the Eye and ENT Hospital of Fudan University said it comes in seven sizes with 0.25-diopter increments. The company said the lens has completed pre-market clinical trials with two years of follow-up at nine Grade 3A hospitals in China.
Developed and made in China
The lens was developed by Wuxi Carl Zeiss Vision Pro Medical Technology Co., Ltd, a joint venture of ZEISS in China, and is set to be manufactured locally. Martin Fischer, president and chief executive of ZEISS Greater China, said the momentum of the Chinese market is driving the company's "In China, for Global" innovation strategy, and that the lens combines optical design with local responsiveness.
